Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness

Robin P F Dullaart; Peter Plomgaard; Rindert de Vries; Björn Dahlbäck; Lars B Nielsen

doi:10.1016/j.cca.2009.06.010

Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness

Robin P F Dullaart, Peter Plomgaard, Rindert de Vries, Björn Dahlbäck, Lars B Nielsen

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

29 Citationer (Scopus)

Abstract

Udgivelsesdato: 2009-Aug

Originalsprog	Engelsk
Tidsskrift	Clinica Chimica Acta
Vol/bind	406
Udgave nummer	1-2
Sider (fra-til)	129-33
Antal sider	4
ISSN	0009-8981
DOI	https://doi.org/10.1016/j.cca.2009.06.010
Status	Udgivet - 2009

Bibliografisk note

Keywords: Adiponectin; Analysis of Variance; Apolipoproteins; Case-Control Studies; Female; Humans; Leptin; Linear Models; Male; Metabolic Syndrome X; Middle Aged; Resistin; Tunica Intima

Adgang til dokumentet

10.1016/j.cca.2009.06.010

Citationsformater

@article{dff4f2a06d4411df928f000ea68e967b,

title = "Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness",

abstract = "BACKGROUND: Apolipoprotein (apo) M may exert anti-atherogenic properties in experimental studies. Its hepatic gene expression may be linked to glucose and lipid metabolism. Plasma apoM is decreased in obese mouse models. We hypothesized that plasma apoM is lower in metabolic syndrome (MetS) subjects, and determined whether intima media thickness (IMT) is associated with apoM. METHODS: In 19 non-diabetic subjects with and 60 non-diabetic subjects without MetS (NCEP, ATP III criteria), the relationships of plasma apoM with obesity, glucose, insulin, lipids and adipokines, as well as with IMT were determined. RESULTS: Plasma apoM was on average 15% lower in subjects with MetS compared to subjects without MetS (p=0.036). ApoM correlated inversely with body mass index and waist circumference (p<0.001), and positively with total cholesterol, LDL cholesterol and apoA-I (p<0.05). ApoM was not significantly correlated with glucose, insulin, leptin, adiponectin or resistin (p>0.20). Age- and sex adjusted IMT was lower in subjects with MetS (p<0.05), but was unrelated to apoM (p=0.68). In a multiple linear regression model that included the presence of both MetS and apoM, IMT was only related to MetS (p=0.05). CONCLUSIONS: Plasma apoM is reduced in MetS. In this study, apoM did not predict subclinical atherosclerosis.",

author = "Dullaart, {Robin P F} and Peter Plomgaard and {de Vries}, Rindert and Bj{\"o}rn Dahlb{\"a}ck and Nielsen, {Lars B}",

note = "Keywords: Adiponectin; Analysis of Variance; Apolipoproteins; Case-Control Studies; Female; Humans; Leptin; Linear Models; Male; Metabolic Syndrome X; Middle Aged; Resistin; Tunica Intima",

year = "2009",

doi = "10.1016/j.cca.2009.06.010",

language = "English",

volume = "406",

pages = "129--33",

journal = "Clinica Chimica Acta",

issn = "0009-8981",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Plasma apolipoprotein M is reduced in metabolic syndrome but does not predict intima media thickness

AU - Dullaart, Robin P F

AU - Plomgaard, Peter

AU - de Vries, Rindert

AU - Dahlbäck, Björn

AU - Nielsen, Lars B

N1 - Keywords: Adiponectin; Analysis of Variance; Apolipoproteins; Case-Control Studies; Female; Humans; Leptin; Linear Models; Male; Metabolic Syndrome X; Middle Aged; Resistin; Tunica Intima

PY - 2009

Y1 - 2009

N2 - BACKGROUND: Apolipoprotein (apo) M may exert anti-atherogenic properties in experimental studies. Its hepatic gene expression may be linked to glucose and lipid metabolism. Plasma apoM is decreased in obese mouse models. We hypothesized that plasma apoM is lower in metabolic syndrome (MetS) subjects, and determined whether intima media thickness (IMT) is associated with apoM. METHODS: In 19 non-diabetic subjects with and 60 non-diabetic subjects without MetS (NCEP, ATP III criteria), the relationships of plasma apoM with obesity, glucose, insulin, lipids and adipokines, as well as with IMT were determined. RESULTS: Plasma apoM was on average 15% lower in subjects with MetS compared to subjects without MetS (p=0.036). ApoM correlated inversely with body mass index and waist circumference (p<0.001), and positively with total cholesterol, LDL cholesterol and apoA-I (p<0.05). ApoM was not significantly correlated with glucose, insulin, leptin, adiponectin or resistin (p>0.20). Age- and sex adjusted IMT was lower in subjects with MetS (p<0.05), but was unrelated to apoM (p=0.68). In a multiple linear regression model that included the presence of both MetS and apoM, IMT was only related to MetS (p=0.05). CONCLUSIONS: Plasma apoM is reduced in MetS. In this study, apoM did not predict subclinical atherosclerosis.

AB - BACKGROUND: Apolipoprotein (apo) M may exert anti-atherogenic properties in experimental studies. Its hepatic gene expression may be linked to glucose and lipid metabolism. Plasma apoM is decreased in obese mouse models. We hypothesized that plasma apoM is lower in metabolic syndrome (MetS) subjects, and determined whether intima media thickness (IMT) is associated with apoM. METHODS: In 19 non-diabetic subjects with and 60 non-diabetic subjects without MetS (NCEP, ATP III criteria), the relationships of plasma apoM with obesity, glucose, insulin, lipids and adipokines, as well as with IMT were determined. RESULTS: Plasma apoM was on average 15% lower in subjects with MetS compared to subjects without MetS (p=0.036). ApoM correlated inversely with body mass index and waist circumference (p<0.001), and positively with total cholesterol, LDL cholesterol and apoA-I (p<0.05). ApoM was not significantly correlated with glucose, insulin, leptin, adiponectin or resistin (p>0.20). Age- and sex adjusted IMT was lower in subjects with MetS (p<0.05), but was unrelated to apoM (p=0.68). In a multiple linear regression model that included the presence of both MetS and apoM, IMT was only related to MetS (p=0.05). CONCLUSIONS: Plasma apoM is reduced in MetS. In this study, apoM did not predict subclinical atherosclerosis.

U2 - 10.1016/j.cca.2009.06.010

DO - 10.1016/j.cca.2009.06.010

M3 - Journal article

C2 - 19539616

VL - 406

SP - 129

EP - 133

JO - Clinica Chimica Acta

JF - Clinica Chimica Acta

SN - 0009-8981

IS - 1-2

ER -